1887

Abstract

The recently described anti-human immunodeficiency virus type 1 (HIV-1) human mAb PG9 and PG16 are cross-clade broadly neutralizing. Therefore, it can be postulated that the targeted epitope(s) are highly conserved among variants of the entire group M. We analysed the sensitivity to PG9 and PG16 of pseudotyped viruses carrying envelope glycoproteins from the viral quasispecies of three HIV-1 clade CRF01_AE-infected patients. The broad heterogeneity in sensitivity to PG9 and PG16, despite closely genetically related envelope glycoproteins issued from single individuals, allowed us to identify two gp120 cross-clade conserved residues, a lysine at position 168 in the V2 loop and an isoleucine at position 215 in the C2 region, whose substitutions were associated with resistance to PG9 and PG16. By site-directed mutagenesis, we confirmed both in clades B and CRF01_AE that the substitutions K168E and I215M have a major impact on PG9 and PG16 neutralization sensitivity of pseudotyped viruses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.042614-0
2012-07-01
2020-09-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/7/1495.html?itemId=/content/journal/jgv/10.1099/vir.0.042614-0&mimeType=html&fmt=ahah

References

  1. Baba T. W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L. A., Posner M. R., Katinger H.other authors 2000; Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6:200–206 [CrossRef][PubMed]
    [Google Scholar]
  2. Barouch D. H. 2008; Challenges in the development of an HIV-1 vaccine. Nature 455:613–619 [CrossRef][PubMed]
    [Google Scholar]
  3. Binley J. M., Lybarger E. A., Crooks E. T., Seaman M. S., Gray E., Davis K. L., Decker J. M., Wycuff D., Harris L.other authors 2008; Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82:11651–11668 [CrossRef][PubMed]
    [Google Scholar]
  4. Bonsignori M., Hwang K.-K., Chen X., Tsao C.-Y., Morris L., Gray E., Marshall D. J., Crump J. A., Kapiga S. H.other authors 2011; Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85:9998–10009 [CrossRef][PubMed]
    [Google Scholar]
  5. Braibant M., Agut H., Rouzioux C., Costagliola D., Autran B., Barin F. 2008; Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies. J Acquir Immune Defic Syndr 47:274–284 [CrossRef][PubMed]
    [Google Scholar]
  6. Braibant M., Xie J., Samri A., Agut H., Autran B., Barin F. 2010; Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology 405:81–92 [CrossRef][PubMed]
    [Google Scholar]
  7. Burton D. R., Desrosiers R. C., Doms R. W., Koff W. C., Kwong P. D., Moore J. P., Nabel G. J., Sodroski J., Wilson I. A., Wyatt R. T. 2004; HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5:233–236 [CrossRef][PubMed]
    [Google Scholar]
  8. Burton D. R., Hessell A. J., Keele B. F., Klasse P. J., Ketas T. A., Moldt B., Dunlop D. C., Poignard P., Doyle L. A.other authors 2011; Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci U S A 108:11181–11186 [CrossRef][PubMed]
    [Google Scholar]
  9. Chaillon A., Braibant M., Moreau T., Thenin S., Moreau A., Autran B., Barin F. 2011; The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J Virol 85:3642–3648 [CrossRef][PubMed]
    [Google Scholar]
  10. Connor R. I., Chen B. K., Choe S., Landau N. R. 1995; Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935–944 [CrossRef][PubMed]
    [Google Scholar]
  11. Corti D., Langedijk J. P. M., Hinz A., Seaman M. S., Vanzetta F., Fernandez-Rodriguez B. M., Silacci C., Pinna D., Jarrossay D.other authors 2010; Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5:e8805 [CrossRef][PubMed]
    [Google Scholar]
  12. Doores K. J., Burton D. R. 2010; Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84:10510–10521 [CrossRef][PubMed]
    [Google Scholar]
  13. Hessell A. J., Poignard P., Hunter M., Hangartner L., Tehrani D. M., Bleeker W. K., Parren P. W. H. I., Marx P. A., Burton D. R. 2009a; Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15:951–954 [CrossRef][PubMed]
    [Google Scholar]
  14. Hessell A. J., Rakasz E. G., Poignard P., Hangartner L., Landucci G., Forthal D. N., Koff W. C., Watkins D. I., Burton D. R. 2009b; Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433 [CrossRef][PubMed]
    [Google Scholar]
  15. Hessell A. J., Rakasz E. G., Tehrani D. M., Huber M., Weisgrau K. L., Landucci G., Forthal D. N., Koff W. C., Poignard P.other authors 2010; Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302–1313 [CrossRef][PubMed]
    [Google Scholar]
  16. Lallemant M., Jourdain G., Le Coeur S., Kim S., Koetsawang S., Comeau A. M., Phoolcharoen W., Essex M., McIntosh K., Vithayasai V.Perinatal HIV Prevention Trial (Thailand) Investigators 2000; A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 343:982–991 [CrossRef][PubMed]
    [Google Scholar]
  17. Li Y., Migueles S. A., Welcher B., Svehla K., Phogat A., Louder M. K., Wu X., Shaw G. M., Connors M.other authors 2007; Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13:1032–1034 [CrossRef][PubMed]
    [Google Scholar]
  18. Liu J., Bartesaghi A., Borgnia M. J., Sapiro G., Subramaniam S. 2008; Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109–113 [CrossRef][PubMed]
    [Google Scholar]
  19. Mascola J. R. 2003; Defining the protective antibody response for HIV-1. Curr Mol Med 3:209–216 [CrossRef][PubMed]
    [Google Scholar]
  20. Mascola J. R., Montefiori D. C. 2010; The role of antibodies in HIV vaccines. Annu Rev Immunol 28:413–444 [CrossRef][PubMed]
    [Google Scholar]
  21. Mascola J. R., Lewis M. G., Stiegler G., Harris D., VanCott T. C., Hayes D., Louder M. K., Brown C. R., Sapan C. V.other authors 1999; Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009–4018[PubMed]
    [Google Scholar]
  22. Mascola J. R., Stiegler G., VanCott T. C., Katinger H., Carpenter C. B., Hanson C. E., Beary H., Hayes D., Frankel S. S.other authors 2000; Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210 [CrossRef][PubMed]
    [Google Scholar]
  23. McLellan J. S., Pancera M., Carrico C., Gorman J., Julien J.-P., Khayat R., Louder R., Pejchal R., Sastry M.other authors 2011; Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336–343 [CrossRef][PubMed]
    [Google Scholar]
  24. Parren P. W., Marx P. A., Hessell A. J., Luckay A., Harouse J., Cheng-Mayer C., Moore J. P., Burton D. R. 2001; Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75:8340–8347 [CrossRef][PubMed]
    [Google Scholar]
  25. Samleerat T., Braibant M., Jourdain G., Moreau A., Ngo-Giang-Huong N., Leechanachai P., Hemvuttiphan J., Hinjiranandana T., Changchit T.other authors 2008; Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J Infect Dis 198:868–876 [CrossRef][PubMed]
    [Google Scholar]
  26. Samleerat T., Thenin S., Jourdain G., Ngo-Giang-Huong N., Moreau A., Leechanachai P., Ithisuknanth J., Pagdi K., Wannarit P.other authors 2009; Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 387:388–394 [CrossRef][PubMed]
    [Google Scholar]
  27. Sanders R. W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K. O., Kwong P. D., Moore J. P. 2002; The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76:7293–7305 [CrossRef][PubMed]
    [Google Scholar]
  28. Scanlan C. N., Pantophlet R., Wormald M. R., Ollmann Saphire E., Stanfield R., Wilson I. A., Katinger H., Dwek R. A., Rudd P. M., Burton D. R. 2002; The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J Virol 76:7306–7321 [CrossRef][PubMed]
    [Google Scholar]
  29. Scheid J. F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T. Y. K., Pietzsch J., Fenyo D., Abadir A.other authors 2011; Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633–1637 [CrossRef][PubMed]
    [Google Scholar]
  30. Thenin S., Samleerat T., Tavernier E., Ngo-Giang-Huong N., Jourdain G., Lallemant M., Barin F., Braibant M. 2012; Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties. Virology 426:12–21 [CrossRef][PubMed]
    [Google Scholar]
  31. Walker L. M., Burton D. R. 2010; Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22:358–366 [CrossRef][PubMed]
    [Google Scholar]
  32. Walker L. M., Phogat S. K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J. L., Wrin T., Simek M. D., Fling S.other authors 2009; Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289 [CrossRef][PubMed]
    [Google Scholar]
  33. Walker L. M., Simek M. D., Priddy F., Gach J. S., Wagner D., Zwick M. B., Phogat S. K., Poignard P., Burton D. R. 2010; A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6:e1001028 [CrossRef][PubMed]
    [Google Scholar]
  34. Walker L. M., Huber M., Doores K. J., Falkowska E., Pejchal R., Julien J.-P., Wang S.-K., Ramos A., Chan-Hui P.-Y.other authors 2011; Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466–470 [CrossRef][PubMed]
    [Google Scholar]
  35. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W. R., Seaman M. S., Zhou T., Schmidt S. D., Wu L.other authors 2010; Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856–861 [CrossRef][PubMed]
    [Google Scholar]
  36. Zhou T., Georgiev I., Wu X., Yang Z.-Y., Dai K., Finzi A., Kwon Y. D., Scheid J. F., Shi W.other authors 2010; Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811–817 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.042614-0
Loading
/content/journal/jgv/10.1099/vir.0.042614-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error